Evidence map›Paper›PMID 42245158›Full record

ArticleFrontiers in pediatrics2026

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations.

Małgorzata Kowacka, Michał Dec, Hubert Arasiewicz

Abstract read
In one paragraph

Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Małgorzata KowackaClinical Department of Pediatric Dermatology and Vascular Anomalies, Faculty of Medical Sciences in Katowice, Medical University of Silesia, John Paul II Children's and Family Health Center, Sosnowiec, Poland.
Michał DecClinical Department of Pediatric Dermatology and Vascular Anomalies, Faculty of Medical Sciences in Katowice, Medical University of Silesia, John Paul II Children's and Family Health Center, Sosnowiec, Poland.
Hubert ArasiewiczClinical Department of Pediatric Dermatology and Vascular Anomalies, Faculty of Medical Sciences in Katowice, Medical University of Silesia, John Paul II Children's and Family Health Center, Sosnowiec, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paradoxical inflammatory reactions, also referred to as flip-flop phenomena, are increasingly recognized complications of biologic therapies targeting specific immune pathways. These reactions are characterized by the emergence of a new inflammatory phenotype with opposing immunologic polarization or by unexpected exacerbation of the underlying disease despite prior therapeutic response. Although numerous case reports have been published, a unified mechanistic framework and a practical clinical approach remain lacking, particularly in pediatric populations. In this narrative review, we synthesize current evidence on the immunopathogenesis of flip-flop reactions, focusing on dynamic interactions between the Th1/Th17, Th2, and interferon-JAK/STAT axes. We propose that paradoxical inflammation can represent a mechanistically consistent consequence of selective immune pressure rather than a coincidental adverse event. Five illustrative pediatric cases are presented as proof of concept, demonstrating distinct pathways leading to eczematous, psoriasiform, and interferon-driven phenotypes during biologic therapy. Based on mechanistic insights and clinical experience, we introduce a practical diagnostic and therapeutic algorithm designed to support early recognition and severity-adapted management of flip-flop reactions. Recognition of immune rebalancing as a therapeutic goal may facilitate rational treatment selection and improve outcomes in both pediatric and adult patients receiving biologic agents.

Indexed as

biologic therapyimmune rebalancingJAK/STATJanus kinase inhibitorsparadoxical adverse eventsparadoxical inflammationpediatric dermatologyphenotypic switch

Identifiers

PMID42245158
PMCPMC13230187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.